TRCT
CERE

Tower Research Capital (TRC)’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Tower Research Capital (TRC)’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33,086
Closed -$1.35M – 6116
2024
Q2 		$1.35M Buy
33,086
+32,358
+4,445% +$1.35M 0.02% 579
2024
Q1 		$30.8K Sell
728
-4,753
-87% -$200K ﹤0.01% 2634
2023
Q4 		$232K Buy
5,481
+4,084
+292% +$117K ﹤0.01% 1973
2023
Q3 		$30.5K Sell
1,397
-2,865
-67% -$71.7K ﹤0.01% 3008
2023
Q2 		$135K Buy
4,262
+1,588
+59% +$48.7K ﹤0.01% 1838
2023
Q1 		$65K Sell
2,674
-1,073
-29% -$31.5K ﹤0.01% 2274
2022
Q4 		$118K Sell
3,747
-902
-19% -$25.5K ﹤0.01% 1707
2022
Q3 		$131K Sell
4,649
-1,435
-24% -$42.7K ﹤0.01% 2317
2022
Q2 		$161K Buy
6,084
+578
+10% +$16.4K ﹤0.01% 1933
2022
Q1 		$192K Sell
5,506
-324
-6% -$9.46K ﹤0.01% 1752
2021
Q4 		$189K Sell
5,830
-6,263
-52% -$221K ﹤0.01% 1815
2021
Q3 		$357K Buy
12,093
+10,539
+678% +$296K 0.01% 1241
2021
Q2 		$40K Buy
1,554
+945
+155% +$13.5K ﹤0.01% 3219
2021
Q1 		$8K Buy
609
+509
+509% +$7.45K ﹤0.01% 4491
2020
Q4 		$2K Buy
+100
New +$1.3K ﹤0.01% 4934

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Tower Research Capital (TRC)'s CERE Position: Q3 2024 in Review

Tower Research Capital (TRC) sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 33,086 shares — an estimated $1.35M sold.

Tower Research Capital (TRC) first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $1.35M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Tower Research Capital (TRC) reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 33,086 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.35M.
  • Tower Research Capital (TRC) first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.35M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2024, filed 14 Nov 2024.